Trending Topic

3D Rendered Medical Illustration of Male Anatomy - Colon Cancer; Ascending Colon.
17 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Rat sarcoma virus (RAS) proteins are a family of prototypical oncogenes frequently mutated in human cancers. Mutations in the RAS gene account for 19% of all pathogenic alterations and are the subject of extensive research in molecular and clinical oncology.1 The RAS family consists of three major isoforms, namely the Harvey rat sarcoma virus (HRAS), the neuroblastoma RAS […]

Janice Mehnert, ASCO 2019 – GITR as a novel checkpoint in immunotherapy

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Jun 11th 2019

At the ASCO 2019 annual meeting, Janice Mehnert discusses GITR as an emerging novel checkpoint in immunotherapy as well as sharing the findings from the recent study investigating the compound MK-4166 (NCT02132754) and considering the next steps in its clinical development.

Questions

1. What are the limitations of current immunotherapies in the treatment of solid tumours? (0:04)
2. What is the rationale for targeting glucocorticoid-induced tumour necrosis factor receptor (GITR)? (0:43)
3. What were the efficacy and safety findings of the recent study investigating MK-4166 as monotherapy or with pembrolizumab in patients with advanced solid tumours? (1:40)
4. What will be the next step in the clinical development of MK-4166? (2:39)
5. What other costimulatory receptors appear to be promising therapeutic targets? (3:23)

Speaker disclosure: Janice Mehnert has acted as a consultant for Merck & Co and participated in advisory boards for BMS, Reserit, Merck, Incyte and AstraZeneca.

Filmed at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting, Chicago, IL, USA.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup